丹参川芎嗪注射液联合左卡尼汀治疗缺血性心肌病心力衰竭患者的疗效观察

Efficacy of Danshen Chuanxiongqin Injection combined with L-carnitine for treatment of patients with ischemic cardiomyopathy and heart failure

目的观察丹参川芎嗪注射液联合左卡尼汀治疗缺血性心肌病心力衰竭患者的临床疗效。方法将120例缺血性心肌病心力衰竭患者随机分为对照组和观察组,每组60例。对照组给予常规药物治疗,观察组在常规治疗基础上加用左卡尼汀和丹参川芎嗪注射液治疗,两组均治疗2周。比较两组患者治疗前后超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)和Ⅲ型前胶原氨基端肽(PⅢNP)、N末端脑钠肽前体(NT-proBNP)及肌钙蛋白T(cTnT)变化水平及心功能情况,观察两组患者治疗期间不良反应的发生情况,并评价两组疗效。结果两组患者治疗后hs-CRP、TNF-α、PⅢNP、NT-proBNP及cTnT水平均低于治疗前,且观察组患者低于对照组(均P<0.05)。两组患者治疗后左心室射血分数、左心室收缩末期内径、左心室舒张末期内径及纽约心脏协会心功能分级均优于治疗前,且观察组优于对照组(P<0.05)。观察组治疗总有效率高于对照组(P<0.05)。治疗期间两组患者均未发生明显的不良反应事件。结论在常规治疗基础上加用丹参川芎嗪注射液联合左卡尼汀治疗缺血性心肌病心力衰竭患者,可以减少炎症因子的释放,稳定心肌细胞,改善患者心功能,疗效显著且安全性高。

Objective To observe the clinical efficacy of Danshen Chuanxiongqin Injection combined with L-carnitine for treating patients with ischemic cardiomyopathy and heart failure. Methods A total of 120 patients with ischemic cardiomyopathy and heart failure were randomly divided into control group and observation group,with 60 cases in each group.The control group was given conventional medication,the observation group was treated with additional L-carnitine and Danshen Chuanxiongqin Injection on the basis of conventional treatment,and both groups were treated for 2 weeks.The two groups were compared in terms of changes in high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor α(TNF-α),procollagen type Ⅲ N-terminal peptide( PⅢNP ),N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin T(cTnT) levels and cardiac function before and after treatment,the incidence of treatment-emergent adverse reactions was observed in the two groups,and efficacy was assessed in both groups. Results After treatment,hs-CRP,TNF-α, PⅢNP ,NT-proBNP and cTnT levels were lower in the two groups compared with those before treatment( P <0.05),and the observation group was superior to the control group(all P <0.05). After treatment,left ventricular ejection fraction,left ventricular end-systolic diameter,left ventricular end-diastolic diameter ,and cardiac function grade assessed by the New York Heart Association criteria were better than those before treatment in both groups,and the observation group was superior to the control group( P <0.05).The observation group reported a higher total effective rate than the control group( P <0.05).No significant treatment-emergent adverse events occurred in the two groups. Conclusion On the basis of conventional therapy,additional use of Danshen Chuanxiongqin Injection combined with L-carnitine can reduce inflammatory factors release,stabilize myocardial cells,and improve cardiac function in the treatment of patients with ischemic cardiomyopathy and heart failure,achieving remarkable efficacy and high safety.